KALA BIO, Inc.
KALA BIO, Inc. a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of therapies for rare and severe eye diseases. The company's lead product candidates include KPI-012, which is in Phase 2b clinical trial for the treatment of persistent corneal epithelial defects; and limbal stem cell deficiency and other rare corneal diseases. Its preclinical d… Read more
KALA BIO, Inc. (0JQ2) - Total Liabilities
Latest total liabilities as of September 2025: $33.69 Million USD
Based on the latest financial reports, KALA BIO, Inc. (0JQ2) has total liabilities worth $33.69 Million USD as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
KALA BIO, Inc. - Total Liabilities Trend (2013–2024)
This chart illustrates how KALA BIO, Inc.'s total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
KALA BIO, Inc. Competitors by Total Liabilities
The table below lists competitors of KALA BIO, Inc. ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Verena Multi Finance Tbk
JK:VRNA
|
Indonesia | Rp2.32 Trillion |
|
Trillium Gold Mines Inc
OTCQX:TGLDF
|
USA | $3.06 Million |
|
Birks Group Inc
NYSE MKT:BGI
|
USA | $233.73 Million |
|
GHST World Inc
PINK:GHST
|
USA | $542.33K |
|
Monumental Minerals Corp
OTCQB:MNMRF
|
USA | $182.62K |
|
REPUBLIC SERVICES - Dusseldorf Stock Exchang
DU:RPU
|
Germany | €20.58 Billion |
|
American Copper Development Corporation
OTCQB:ACDXF
|
USA | $464.64K |
Liability Composition Analysis (2013–2024)
This chart breaks down KALA BIO, Inc.'s total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.75 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -3.89 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 1.35 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how KALA BIO, Inc.'s debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for KALA BIO, Inc. (2013–2024)
The table below shows the annual total liabilities of KALA BIO, Inc. from 2013 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $43.15 Million | -10.93% |
| 2023-12-31 | $48.45 Million | -28.60% |
| 2022-12-31 | $67.85 Million | -44.67% |
| 2021-12-31 | $122.62 Million | +0.83% |
| 2020-12-31 | $121.61 Million | -2.42% |
| 2019-12-31 | $124.63 Million | +7.46% |
| 2018-12-31 | $115.98 Million | +338.42% |
| 2017-12-31 | $26.45 Million | -80.27% |
| 2016-12-31 | $134.09 Million | +841.58% |
| 2015-12-31 | $14.24 Million | +68.33% |
| 2014-12-31 | $8.46 Million | +23.14% |
| 2013-12-31 | $6.87 Million | -- |